Exagen Inc.
NASDAQ:XGNMedical - Diagnostics & Research
+$0.16 today
- Market cap
- $99.50M
- Beta
- 2.02
- P/E (TTM)
- -5.2
- EPS (TTM)
- -$0.85
Volume 0.47M
Average 0.39M
XGN Net Margin
Net income as a percentage of revenue, showing how much of each sales dollar becomes profit.
Exagen Inc.NASDAQ: XGN
Net Margin · Q1 FY2026 · quarter ended Mar 2026
Net margin widens to -22.9%
Net margin was -22.9% in Q1 FY2026, up 1.3 pp from a year earlier. On a trailing-twelve-month basis it was -29.5%, down 2.2 pp year over year. Over 3 fiscal years it widened by 74.0 pp.
Context
- Net margin widened in 2 of the last 3 fiscal years.
What to watch
Whether net margin reaches the consensus estimate from 6 analysts of -21.1% for the fiscal year ending Dec 2026, up from -30.0% in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -22.9%+5.2 pp QoQ
- Last fiscal yearDec 2025
- -30.0%-2.8 pp YoY
- LTMMar 2026
- -29.5%-2.2 pp YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +1.3 pp | -0.9 pp | -2.2 pp |
| 1 year | -2.8 pp | +8.8 pp | +11.6 pp |
| 3 years | +74.0 pp | +20.0 pp | -54.0 pp |
| 5 years | +27.9 pp | — | |
| 10 years | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Margin history
Percent of revenue · from the income statement
- Latest · FY2025
- -30.0%
- Year-over-year change
- -2.8pp
| Period | Period end | Net Margin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | -30.0% | -2.8pp |
| FY2024 | 2024-12-31 | -27.2% | +17.9pp |
| FY2023 | 2023-12-31 | -45.1% | +58.9pp |
| FY2022 | 2022-12-31 | -104.0% | -48.4pp |
| FY2021 | 2021-12-31 | -55.6% | — |
Net Margin vs competitors
How XGN compares with its peers on the latest reported figures
- XGN's LTM Mar 2026 net margin of -29.5% is the 3rd highest of the 11 companies compared; the peer median is -43.9%.
- Its year-over-year change of -2.2 pp is the 7th highest of 10, against a peer median of +11.2 pp.
- Over three fiscal years its change of +74.0 pp compares with a peer median of +13.4 pp.
| Company | Period | LTM level | YoY | 3-year change |
|---|---|---|---|---|
| LTM Jun 2026 | -6.8% | +8.3 pp | +13.4 pp | |
| LTM Mar 2026 | -25.2% | — | +74.8 pp | |
| LTM Mar 2026 | -29.5% | -2.2 pp | +74.0 pp | |
| FY2025 | -31.1% | +11.2 pp | +87.8 pp | |
| LTM Mar 2026 | -31.2% | -18.8 pp | -19.1 pp | |
| LTM Mar 2026 | -41.1% | +19.8 pp | +72.0 pp | |
| LTM Mar 2026 | -46.8% | +16.4 pp | +71.2 pp | |
| LTM Mar 2026 | -69.5% | +22.7 pp | -1.9 pp | |
| LTM Mar 2026 | -110.0% | -88.0 pp | -104.5 pp | |
| LTM Mar 2026 | -832.6% | -100.2 pp | -537.5 pp | |
BIOABioAge Labs, Inc. | LTM Mar 2026 | -871.8% | +4024.5 pp | — |
| Peer median (excluding XGN) | -43.9% | +11.2 pp | +13.4 pp | |
Competitors are the stored peer set for XGN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 48.3M | 45.56M | 52.55M | 55.64M | 66.58M |
| Cost of Revenue | 20.59M | 24.21M | 23.09M | 22.53M | 27.78M |
| Gross Profit | 27.71M | 21.35M | 29.46M | 33.11M | 38.8M |
| Gross Margin | 57.4% | 46.9% | 56.1% | 59.5% | 58.3% |
| Research & Development | 7.24M | 9.88M | 4.87M | 5.38M | 6.25M |
| Selling, General & Admin | 44.54M | 52.02M | 47.43M | 41.37M | 46.62M |
| Operating Expenses | 51.78M | 67.4M | 52.29M | 46.75M | 52.87M |
| Depreciation & Amortization | 948K | 1.56M | 2.17M | 1.72M | 2.12M |
| EBITDA | (23.1M) | (43.66M) | (19.15M) | (11.15M) | (13.46M) |
| EBITDA Margin | -47.8% | -95.8% | -36.4% | -20.0% | -20.2% |
| Operating Income | (24.07M) | (46.05M) | (22.84M) | (13.64M) | (14.07M) |
| Operating Margin | -49.8% | -101.1% | -43.5% | -24.5% | -21.1% |
| Interest Income | 16K | 830K | 1.52M | 767K | 289K |
| Interest Expense | 2.63M | 2.45M | 2.34M | 2.23M | 4.32M |
| Other Income / Expenses | (2.61M) | (1.62M) | (819K) | (1.47M) | (5.83M) |
| Income Before Tax | (26.68M) | (47.67M) | (23.66M) | (15.1M) | (19.9M) |
| Pre-Tax Margin | -55.2% | -104.6% | -45.0% | -27.1% | -29.9% |
| Income Tax Expense | 175K | (282K) | 33K | 12K | 51K |
| Net Income | (26.85M) | (47.39M) | (23.69M) | (15.12M) | (19.95M) |
| Net Margin | -55.6% | -104.0% | -45.1% | -27.2% | -30.0% |
| EPS (Basic) | (1.68) | (2.77) | (1.34) | (0.83) | (0.93) |
| EPS (Diluted) | (1.68) | (2.77) | (1.34) | (0.83) | (0.93) |
| Weighted Avg Shares | 15.97M | 17.08M | 17.68M | 18.2M | 21.56M |
| Weighted Avg Shares (Diluted) | 15.97M | 17.08M | 17.68M | 18.2M | 21.56M |
Exagen Inc.
NASDAQ:XGN
Intrinsic Alpha fair value
Locked
Current Price
$3.90
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.